|
|
THERAPIES FROM A CRITICAL VIEW POINT
|
|
Clopidogrel (ISCOVER, PLAVIX): Bad choice after aspirin-induced bleeding ulcers
Glucose-insulin-potassium infusions without benefit after myocardial infarction
|
|
|
NEW ON THE MARKET
|
|
Solifenacin (VESIKUR) and Darifenacin (EMSELEX) for overactive bladder
|
|
|
REVIEW
|
|
Drug therapy of cancer pain (I)
|
|
|
IN BRIEF
|
|
Cardiotoxicity of Etoricoxib (ARCOXIA)
Reviparin (CLIVARIN) after myocardial infarction
Duloxetin (YENTREVE): Not licensed for stress incontinence by FDA
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Frequent serious local adverse events after pneumococcal revaccination
|
|
|
SIDE EFFECTS
|
|
Ezetemib (EZETROL): Hepatitis, rhabdomyolysis and other serious adverse events
Osteonecrosis of the jaw associated with use of bisphosphonates: a class effect?
Increased mortality associated with Alzheimer-drug Galantamin (REMINYL)
|
|